Search

Displaying results 791 - 800 of 3872 in total
  1. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...

  2. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    Anascorp is produced from equine IgG antibodies. … Because initial development and use of this product in Mexico, venoms from several Centruroides species endemic to Mexico are pooled and diluted [L2207].

  3. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Synonyms: N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
  4. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular

  5. Drug

    Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB11000
    ApprovedInvestigationalWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.

    Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 Kit
  6. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    Recombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo. The vaccine comprises two antigens - the other being recombinant stabilized RSV A prefusion F antig...

  7. Drug

    Ritonavir

    go.drugbank.com/drugs/DB00503
    ApprovedInvestigational

    In Canada, ritonavir is also available as a fixed-dose combination product with [DB09296], [DB09183], and [DB09297] as the Health Canada-approved, commercially available product Holkira Pak. … It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules.

    Mixtures: VIRONTAR N COMPRIMIDOS RECUBIERTOS, VIRONTAR N COMPRIMIDOS RECUBIERTOS
  8. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    In Canada, paritaprevir is also available as a fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the Health Canada-approved, commercially available product Holkira Pak. … Paritaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie.

    Synonyms: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo
  9. Drug

    Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB10600
    ApprovedWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.

    Mixtures: Medical Provider Single Use EZ Flu Shot Afluria 2016-2017
  10. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor … [L64112] The European Commission granted marketing authorization on August 24, 2026 for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged 5 years and older